Rock Springs Capital Management LP Q1 2024 Filing

Filed May 15, 2024

Portfolio Value

$3.9B

Holdings

113

Report Date

Q1 2024

Filing Type

13F-HR

All Holdings (113 positions)

#StockSharesValue% PortfolioType
101
AMLXAMYLYX PHARMACEUTICALS INC
1,011,412$2.9T72925.17%
102
TVTX 2.5 09/15/25TRAVERE THERAPEUTICS INC
3,250,000$2.8T72142.35%
103
BMEABIOMEA FUSION INC
181,147$2.7T68754.86%
104
NVV1NOVAVAX INC
537,625$2.6T65243.68%
105
CYPHLEAP THERAPEUTICS INC
911,937$2.4T61585.35%
106
SPRBSPRUCE BIOSCIENCES INC
2,609,125$2.1T52058.67%
107
NBIX 2.25 05/15/24NEUROCRINE BIOSCIENCES INC
1,000,000$1.8T45882.73%
108
VIGLVIGIL NEUROSCIENCE INC
471,958$1.6T40859.10%
109
XLOXILIO THERAPEUTICS INC
1,440,759$1.6T39504.46%
110
OKURRENEO PHARMACEUTICALS INC
751,730$1.2T31681.16%
111500,000$473.9B12030.66%
112
TLPHTALPHERA INC
316,460$326.0B8275.37%
113
NUVB/WSNUVATION BIO INC
134,028$40.5B1029.31%
PreviousPage 2 of 2